Low-Dose Aspirin Research

This systematic review and meta-analysis pooled data from 13 randomized controlled trials involving over 164,000 participants to evaluate the benefits and risks of low-dose aspirin for primary prevention of cardiovascular disease. The analysis included trial sequential analysis (TSA) to assess the robustness of findings.

The results showed that low-dose aspirin significantly reduced the risk of major adverse cardiovascular events (MACE), myocardial infarction, and ischemic stroke in individuals without established cardiovascular disease. However, aspirin also significantly increased the risk of major bleeding events, including gastrointestinal and intracranial hemorrhage.

Trial sequential analysis confirmed that the evidence for both cardiovascular benefit and bleeding risk had crossed the monitoring boundaries, indicating firm conclusions. The authors concluded that the decision to use low-dose aspirin for primary prevention should involve careful individualized assessment, weighing cardiovascular risk reduction against bleeding risk.

This meta-analysis focused specifically on the role of low-dose aspirin in primary prevention of cardiovascular disease among patients with diabetes mellitus, a population at elevated baseline cardiovascular risk. The study stratified results by baseline cardiovascular risk level to determine where aspirin provides the greatest net benefit.

The pooled analysis found that low-dose aspirin significantly reduced the risk of major adverse cardiovascular events (MACE) in diabetic patients overall. When stratified by baseline risk, the absolute benefit was greater in patients with higher cardiovascular risk scores, supporting a risk-stratified approach to aspirin prescribing in this population.

However, the increased bleeding risk associated with aspirin was present across all risk strata. The authors concluded that in diabetic patients, aspirin for primary prevention should be considered primarily in those with elevated cardiovascular risk where the expected benefit outweighs the bleeding hazard, aligning with current guideline recommendations for individualized decision-making.

This umbrella review synthesized evidence from 72 systematic reviews and meta-analyses covering a wide range of health outcomes associated with low-dose aspirin use. The study used a comprehensive grading system to assess the strength of evidence across outcomes.

Strong evidence supported aspirin's role in reducing major cardiovascular events, myocardial infarction, and colorectal cancer incidence and mortality. The cancer-preventive effects were notable, with consistent risk reductions observed across multiple meta-analyses. Aspirin also showed suggestive evidence of benefit for preeclampsia prevention.

On the harm side, strong evidence confirmed that low-dose aspirin increases the risk of major gastrointestinal bleeding, intracranial bleeding, and hemorrhagic stroke. The authors emphasized that the overall benefit-risk balance depends heavily on individual patient characteristics, including age, cardiovascular risk, and bleeding history. This remains one of the most comprehensive evaluations of aspirin's broad health effects to date.

This landmark analysis pooled individual patient data from 10 randomized trials to examine how body weight affects aspirin's efficacy for cardiovascular prevention.

Key Findings:

Weight-Dependent Efficacy:

• Low-dose aspirin (75-100mg) reduced vascular events by 23% in people weighing 50-69kg
• No significant benefit was seen in people weighing 70kg or more on low-dose aspirin
• People over 70kg actually had increased case fatality from first cardiovascular events on low-dose aspirin

Dose Recommendations by Weight:

• 50-69kg: Low-dose (75-100mg) effective
• 70-89kg: Higher doses (300-325mg) may be needed
• 90kg+: Even higher doses possibly required

Cancer Prevention:

• Low-dose aspirin reduced colorectal cancer risk only in those under 70kg
• Higher doses needed for cancer prevention in heavier individuals

Implications:

This study fundamentally changed how aspirin should be prescribed, suggesting that one-size-fits-all dosing is inappropriate. The findings explain why some large trials showed no benefit, they used low doses in predominantly heavier populations.

ASPREE was a landmark randomized, double-blind, placebo-controlled trial examining whether daily low-dose aspirin (100mg) would extend healthy, independent life in older adults.

Study Design:

• 19,114 community-dwelling adults aged 70+ (65+ for US minorities)
• Median follow-up: 4.7 years
• Primary endpoint: Disability-free survival (survival free of dementia or persistent physical disability)

Key Results:

No Benefit for Primary Endpoint:

• Disability-free survival: No significant difference between aspirin and placebo
• Aspirin group: 21.5 events per 1000 person-years
• Placebo group: 21.2 events per 1000 person-years

Increased Bleeding:

• Major hemorrhage: 3.8% aspirin vs 2.8% placebo (HR 1.38)
• Upper GI bleeding was the most common site
• Intracranial bleeding also increased

Unexpected Cancer Signal:

• Higher cancer-related mortality in aspirin group (3.1% vs 2.3%)
• This finding was unexpected and requires further investigation

Conclusions:

This trial was pivotal in changing guidelines to recommend against initiating aspirin for primary prevention in adults 70 and older. The bleeding risks clearly outweighed any potential benefits in this population.

This large prospective cohort study examined the association between long-term aspirin use and cancer incidence using data from the Nurses' Health Study and Health Professionals Follow-up Study.

Study Population:

• 135,965 participants
• Follow-up: Up to 32 years
• 88,084 women and 47,881 men

Key Findings:

Overall Cancer Risk:

• Regular aspirin use (≥2 tablets/week) for 6+ years: 3% lower total cancer incidence
• Most benefit seen after 6 years of continuous use
• Benefit persisted after stopping aspirin

Colorectal Cancer:

• 19% reduction in colorectal cancer risk with regular use
• Strongest effect seen with doses of 0.5-1.5 standard aspirin tablets/day
• Benefit appeared after ~6 years of use

Gastrointestinal Cancers:

• 15% reduction in overall GI tract cancers
• Effects seen for esophageal, stomach, and colorectal cancers

Population Impact:

• If all US adults 50-64 took aspirin, an estimated 29,800 fewer GI cancers would occur over 10 years
• This must be balanced against approximately 5,400 excess GI bleeding events

Conclusions:

Long-term aspirin use is associated with meaningful reductions in cancer risk, particularly colorectal cancer. However, benefits take years to emerge and must be weighed against bleeding risks.

This authoritative review article summarizes the current understanding of low-dose aspirin's mechanisms and clinical applications for cardiovascular prevention.

Mechanism of Action:

COX-1 Inhibition:

• Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1)
• This blocks production of thromboxane A2 in platelets
• Thromboxane A2 normally promotes platelet aggregation and vasoconstriction
• Because platelets cannot synthesize new COX-1, effect lasts platelet lifetime (7-10 days)

Why Low Doses Work:

• Even 75mg aspirin inhibits >95% of platelet thromboxane production
• Higher doses don't improve platelet inhibition but increase side effects
• The irreversible nature means once-daily dosing is sufficient

Additional Effects:

• COX-2 inhibition (at higher doses): Anti-inflammatory
• Nitric oxide effects: May improve endothelial function
• NF-κB inhibition: Reduces inflammatory gene expression

Clinical Evidence Summary:

• Primary prevention: 12% reduction in major vascular events
• Secondary prevention: 25% reduction in recurrent events
• Benefits must be balanced against bleeding risk

Current Recommendations:

• Secondary prevention: Clearly beneficial
• Primary prevention: Risk-benefit assessment needed
• Consider body weight when dosing
• Age is a critical factor in risk-benefit calculation